×
About 3,140 results

ALLMedicine™ Polycythemia Vera Center

Research & Reviews  987 results

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis ...
https://clinicaltrials.gov/ct2/show/NCT04446650

Jan 21st, 2022 - The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This ...

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
https://clinicaltrials.gov/ct2/show/NCT05198960

Jan 20th, 2022 - Philadelphia-negative myeloproliferative neoplasms (MPN) are frequent and chronic myeloid malignancies including Polycythemia Vera (PV), essential thrombocythemia (ET), Primary Myelofibrosis (PMF) and Prefibrotic myelofibrosis (PreMF). These MPNs ...

Hospital incidence and medical costs of polycythemia vera in Spain: a retrospective dat...
https://doi.org/10.1080/14737167.2022.2029413
Expert Review of Pharmacoeconomics & Outcomes Research; Darbà J, Marsà A

Jan 18th, 2022 - Polycythemia vera (PV) is one of the most common chronic myeloproliferative neoplasms, yet, little data is available on the epidemiology of PV in Spain and the costs of its management. This study aimed to evaluate the hospital incidence and mortal...

Polycythemia vera presenting with pulmonary embolism and splenic infarction: a case rep...
https://doi.org/10.1177/03000605211072801
The Journal of International Medical Research; Huang P, Li Y

Jan 14th, 2022 - Pulmonary embolism and splenic infarction are rare in patients with polycythemia vera. We herein describe a man in his early 60s whose main symptoms were chest tightness, cough, and sputum expectoration. Antibiotics, bronchodilators, and mucoactiv...

Prevalence of CYLD mutations in Vietnamese patients with polycythemia vera.
https://doi.org/10.17219/acem/144027
Advances in Clinical and Experimental Medicine : Official... Trang DT, Giang NH et. al.

Jan 14th, 2022 - Polycythemia vera (PV) is characterized by increased proliferation and accumulation of erythroid and mature myeloid cells and megakaryocyte in the bone marrow and peripheral blood. The JAK2V617F mutation is present in most PV patients. Deubiquitin...

see more →

Guidelines  3 results

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Onco...
https://doi.org/10.6004/jnccn.2016.0169
Journal of the National Comprehensive Cancer Network : JN... Mesa R, Jamieson C et. al.

Dec 14th, 2016 - Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagn...

Prophylaxis and management of venous thromboembolism in patients with myeloproliferativ...
https://doi.org/10.1007/s00277-014-2224-8
Annals of Hematology; Kreher S, Ochsenreither S et. al.

Oct 14th, 2014 - Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) like polycythemia vera and essential thrombocythemia are at increased risk of arterial and venous thrombosis. Strategies of prevention may consist of platelet aggreg...

see more →

Drugs  8 results see all →

Clinicaltrials.gov  46 results

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis ...
https://clinicaltrials.gov/ct2/show/NCT04446650

Jan 21st, 2022 - The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This ...

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
https://clinicaltrials.gov/ct2/show/NCT05198960

Jan 20th, 2022 - Philadelphia-negative myeloproliferative neoplasms (MPN) are frequent and chronic myeloid malignancies including Polycythemia Vera (PV), essential thrombocythemia (ET), Primary Myelofibrosis (PMF) and Prefibrotic myelofibrosis (PreMF). These MPNs ...

A Study to Evaluate IONIS-TMPRSS6-LRx (ISIS 702843) in Patients With Polycythemia Vera
https://clinicaltrials.gov/ct2/show/NCT05143957

Jan 12th, 2022 - This is a Phase 2a, multi-center, randomized, open-label study of IONIS-TMPRSS6-LRx in up to 40 participants with PD-PV. The study consists of 3 periods: 1) Screening Period: up to 7 weeks; 2) Treatment Period: 33 weeks + a 4-week post-last dose v...

Extended Access of Momelotinib in Adults With Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT03441113

Jan 11th, 2022 - The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/...

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors
https://clinicaltrials.gov/ct2/show/NCT05153343

Dec 10th, 2021 - Flonoltinib Maleate (FM) targets Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). FM is a dual target inhibitor of JAK2/FLT3.FM has the activity of inhibiting JAK2 signaling pathway, and pharmacodynamics evaluation also confirmed that ...

see more →

News  209 results

FDA Approves New Interferon for Polycythemia Vera
https://www.medscape.com/viewarticle/963368

Nov 19th, 2021 - The Food and Drug Administration on November 12 approved ropeginterferon alfa-2b-njft (Besremi), a monopegylated, long-acting interferon, for adults with polycythemia vera, according to an agency press release. Besremi has a longer half-life than ...

FDA approves new interferon for polycythemia vera
https://www.mdedge.com/hematology-oncology/article/248870/bleeding-disorders/fda-approves-new-interferon-polycythemia-vera
M. Alexander Otto

Nov 18th, 2021 - The Food and Drug Administration on Nov. 12 approved ropeginterferon alfa-2b-njft (Besremi), a monopegylated, long-acting interferon, for adults with polycythemia vera, according to an agency press release.

Pegylated Interferon Wins FDA Approval for Polycythemia Vera
https://www.medpagetoday.com/hematologyoncology/hematology/95675

Nov 15th, 2021 - The FDA granted a first-ever approval of an interferon for the rare blood disorder polycythemia vera (PV), also making ropeginterferon alfa-2b-njft (Besremi) the first approved PV therapy that patients can receive regardless of treatment history. ...

FDA Approves Ropeginterferon Alfa-2b-njft for Polycythemia Vera
https://www.onclive.com/view/fda-approves-ropeginterferon-alfa-2b-njft-for-polycythemia-vera

Nov 13th, 2021 - The FDA has approved ropeginterferon alfa-2b-njft (Besremi) for use as a treatment in patients with polycythemia vera.1 The regulatory decision was based on safety from the PEGINVERA and PROUD/ CONTINUATION-PV studies and efficacy findings from t...

Dr. Richard T. Silver Discusses the Use of Interferons in MPNs
https://www.onclive.com/view/dr-richard-t-silver-discusses-the-use-of-interferons-in-mpns

Oct 6th, 2021 - Richard T. Silver, MD, Professor of Medicine, Director, Leukemia and Myleoproliferative Center, New York Presbyterian-Weill Cornell Medical Center, discusses the use of interferons in myeloproliferative neoplasms (MPNs). Silver says that the thou...

see more →

Patient Education  3 results see all →